MLEC
Moolec Science S.A.
NASDAQ · Healthcare · Biotechnology · LU
$6.93
−2.94%Year over year
Reported trailing growth
- Revenue
- +170.4%
- EBITDA
- +23.9%
- EBIT
- -74.3%
- EPS
- -27.0%
- Free cash flow
- +52.7%
- Operating cash flow
- +55.2%
Forward estimates
Based on analyst estimates
- Revenue
- -60.0%
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +1819.9%
- EBITDA
- —
- EBIT
- -15.9%
- Net income
- —
- EPS
- —
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2025